"Aniline Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that include the aminobenzene structure.
| Descriptor ID |
D000814
|
| MeSH Number(s) |
D02.092.146
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aniline Compounds".
Below are MeSH descriptors whose meaning is more specific than "Aniline Compounds".
This graph shows the total number of publications written about "Aniline Compounds" by people in this website by year, and whether "Aniline Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 2 | 0 | 2 |
| 2001 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 2 | 2 |
| 2008 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 2 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2024 | 2 | 1 | 3 |
| 2025 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aniline Compounds" by people in Profiles.
-
Dela Cruz MC, Yao X, Roberts N, Iheukwumere P, Carmouche A, Medina PM, Biliran H. TLE1 drives EGFR-TKI resistance in EGFR-mutant lung adenocarcinoma through epithelial to mesenchymal transition. Biochem Biophys Res Commun. 2025 Aug 15; 775:152146.
-
Nathani A, Sun L, Li Y, Lazarte J, Aare M, Singh M. Targeting EGFR-TKI resistance in lung cancer: Role of miR-5193/miR-149-5p loaded NK-EVs and Carboplatin combination. Int J Pharm. 2025 Apr 30; 675:125573.
-
Nathani A, Khan I, Tanimoto MH, Mej?a JAA, DE Miranda AM, Rishi A, Dev S, Bastos JK, Singh M. Antitumor Potential of Guttiferone E Combined With Carboplatin Against Osimertinib-resistant H1975 Lung Cancer Through Apoptosis. Anticancer Res. 2024 Oct; 44(10):4175-4188.
-
Bhatt HN, Diwan R, Estevao IL, Dong R, Smith J, Xiao C, Agarwal SK, Nurunnabi M. Cadherin-11 targeted cell-specific liposomes enabled skin fibrosis treatment by inducing apoptosis. J Control Release. 2024 Jun; 370:110-123.
-
da Silva RAG, Stocks CJ, Hu G, Kline KA, Chen J. Bosutinib Stimulates Macrophage Survival, Phagocytosis, and Intracellular Killing of Bacteria. ACS Infect Dis. 2024 05 10; 10(5):1725-1738.
-
Kommineni N, Nottingham E, Bagde A, Patel N, Rishi AK, Dev SRS, Singh M. Role of nano-lipid formulation of CARP-1 mimetic, CFM-4.17 to improve systemic exposure and response in osimertinib resistant non-small cell lung cancer. Eur J Pharm Biopharm. 2021 Jan; 158:172-184.
-
Chand HS, Mebratu YA, Kuehl PJ, Tesfaigzi Y. Blocking Bcl-2 resolves IL-13-mediated mucous cell hyperplasia in a Bik-dependent manner. J Allergy Clin Immunol. 2017 11; 140(5):1456-1459.e9.
-
Sviatenko LK, Gorb L, Hill FC, Leszczynska D, Okovytyy SI, Leszczynski J. Alkaline hydrolysis of hexahydro-1,3,5-trinitro-1,3,5-triazine: M06-2X investigation. Chemosphere. 2015 Sep; 134:31-8.
-
Basant N, Lin X, Reid TE, Karla PK, Wang XS. Discovery of a Novel HDAC2 Inhibitor by a Scaffold-Merging Hybrid Query. Comb Chem High Throughput Screen. 2015; 18(7):693-700.
-
Tarpley M, Abdissa TT, Johnson GL, Scott JE. Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines. Anticancer Res. 2014 Apr; 34(4):1629-35.